One space that continues to see dramatically rising fresh interest in the healthcare technology space is bioelectronic medicine – essentially, the use of electricity as a stimulus to tap into the body’s electrochemical operating system and impact its functionality and well-being.
The idea of electrically stimulating the body to alleviate illness is not new. Doctors have implanted patients with pacemakers, deep-brain stimulators, and other electrical devices for decades. Vagus nerve stimulation itself is currently US Food and Drug Administration (FDA)-approved for epilepsy and treatment-resistant depression. But these were crude and simplistic wanderings in the dark in terms of any real “science” of communicating electrically with the body.
But the field is now on much firmer ground, backed by top researchers and big health science companies with deep pockets. In addition, because bioelectronic medicine has well-established applications in chronic pain management,
Even so, for public market investors, there are very few choices on the menu that represent pure-play vehicles to attempt to capture the expected growth in the field to come.
One stock that fits this bill and that has so far flown under the radar on the OTC after starting its trading journal late last year is Electromedical Technologies Inc (OTCMKTS:EMED) may be the most interesting player in the emerging space of bioelectronic medicine – a first-mover leading-edge player in Bioelectronic medicine.
Paydirt!
Electromedical Technologies Inc (OTCMKTS:EMED) is a relative unknown in the market to most people. But that doesn’t in any way mean it will stay that way — especially after its most recent release:
Electromedical Technologies, Inc. (OTCMKTS:EMED), a pioneer in the development and manufacturing of bioelectronic devices, is pleased to announce that it continues to find strong interest for its FDA cleared WellnessPro+ device line as a bioelectronic chronic pain solution from top professional athletes in the NBA, NFL, NHL, PGA, and PBR. As a result, the Company has ordered an additional 1,000 units to enter production to meet expected rising demand.
“We are excited to see use and growing demand among some of the world’s top athletes for our proprietary bioelectronic chronic pain solution, because it represents validation from those who demand performance in their treatment options,” noted Matthew Wolfson, Founder and CEO of Electromedical Technologies. “They can’t afford the risks associated with opioid-based drugs, but they need results. Word of mouth in locker rooms and team meetings has been a very valuable marketing tool because our device delivers a complete solution to chronic pain without any dangerous or harmful side effects – it helps players get up off the bench and back into the game fast.”
According to the release, Management notes that the Company has seen interest from top athletes and trainers across the professional sports universe. The Company is in discussions with several individuals about cultivating public endorsements or brand ambassador relationships based on the strong feedback Electromedical Technologies has received from those using the WellnessPro+ device as a pain solution to help drive performance in professional sports competition.
This is bigger news than it might seem at first – and at first, it seems pretty big considering this is a company worth less than $20 million total. To have potential brand tie-in taking shape with the likes of the NFL, NBA, NHL, PGA, and PBR is about as big as it gets. But there’s another point here to appreciate.
Get Shorty
The last paragraph in the company’s press release notes that it is “in discussions with several individuals about cultivating public endorsements or brand ambassador relationships based on the strong feedback Electromedical Technologies has received from those using the WellnessPro+ device as a pain solution to help drive performance in professional sports competition.”
You never know who’s using this product. But imagine being short EMED shares on the day LeBron James or Tom Brady comes out and tweets about the WellnessPro+. That would not be a good day.
A stock like this is ultimately all about visibility and exposure. Presuming the technology works, the path to growth is about credible, trusted, well-known people telling the world it works.
Just the specter of such an event involving a major sports figure has to hang over shorts in this stock like the sword of Damocles.
Finally, don’t forget about the fact that this release also contains the guidance that the company has had to produce more devices than planned to keep up with demand. This is a name that has only just started to engage in commercial-stage activity.
Another factor that could generate a spotlight would be the revelation of serious revenue growth getting going. We don’t know anything more than you do at this point. But it’s not unreasonable to extrapolate that potential from what was stated in the press release.
COMPENSATION DISCLOSURE: Section 17(b) of the 1933 Act requires publishers to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b): Tiger Global Management Partners LLC has compensated a third party to produce and present weekly content for various companies for the publication. For more information, please click here. In addition, this article is part of JournalTranscript.com Networks. Read the JournalTranscript.com Networks Disclaimer.
